<SEC-DOCUMENT>0001746473-22-000009.txt : 20220228
<SEC-HEADER>0001746473-22-000009.hdr.sgml : 20220228
<ACCEPTANCE-DATETIME>20220228160749
ACCESSION NUMBER:		0001746473-22-000009
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20220228
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220228
DATE AS OF CHANGE:		20220228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PLIANT THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001746473
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				474272481
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39303
		FILM NUMBER:		22689396

	BUSINESS ADDRESS:	
		STREET 1:		260 LITTLEFIELD AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-481-6770

	MAIL ADDRESS:	
		STREET 1:		260 LITTLEFIELD AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>plrx-20220228.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:2ec302b2-b7ae-47b4-961d-2f7a10122ea7,g:5288333c-f784-4bbc-96a0-5f543685bee2,d:7485a5c6bd0b4e9b9caf1a144cfde7d5--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>plrx-20220228</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ic10c089cca4b439a8aac7cbb76b6909e_D20220228-20220228" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjc0ODVhNWM2YmQwYjRlOWI5Y2FmMWExNDRjZmRlN2Q1L3NlYzo3NDg1YTVjNmJkMGI0ZTliOWNhZjFhMTQ0Y2ZkZTdkNV80L2ZyYWc6OTIyNmFiZGVjMmYwNDI0ZmE5NmU2M2FjYzQwMzc3MzYvdGFibGU6NjIwZjFjYmQyOTgwNDU4NjhlOTM1NzE3MThhYzQ0MWIvdGFibGVyYW5nZTo2MjBmMWNiZDI5ODA0NTg2OGU5MzU3MTcxOGFjNDQxYl8wLTEtMS0xLTI5MzAw_fff81ad6-bb31-48ce-bb6b-3e049bd27baf">0001746473</ix:nonNumeric><ix:nonNumeric contextRef="ic10c089cca4b439a8aac7cbb76b6909e_D20220228-20220228" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjc0ODVhNWM2YmQwYjRlOWI5Y2FmMWExNDRjZmRlN2Q1L3NlYzo3NDg1YTVjNmJkMGI0ZTliOWNhZjFhMTQ0Y2ZkZTdkNV80L2ZyYWc6OTIyNmFiZGVjMmYwNDI0ZmE5NmU2M2FjYzQwMzc3MzYvdGFibGU6NjIwZjFjYmQyOTgwNDU4NjhlOTM1NzE3MThhYzQ0MWIvdGFibGVyYW5nZTo2MjBmMWNiZDI5ODA0NTg2OGU5MzU3MTcxOGFjNDQxYl8xLTEtMS0xLTI5MzAw_68fa1791-48a1-4f6c-bb03-20ad304a5225">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="plrx-20220228.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ic10c089cca4b439a8aac7cbb76b6909e_D20220228-20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-28</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i7485a5c6bd0b4e9b9caf1a144cfde7d5_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ic10c089cca4b439a8aac7cbb76b6909e_D20220228-20220228" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjc0ODVhNWM2YmQwYjRlOWI5Y2FmMWExNDRjZmRlN2Q1L3NlYzo3NDg1YTVjNmJkMGI0ZTliOWNhZjFhMTQ0Y2ZkZTdkNV8xL2ZyYWc6ZjJhN2RjYjI2Y2QzNDVkZDllYjFhYTNjZDJjNTRjOGMvdGV4dHJlZ2lvbjpmMmE3ZGNiMjZjZDM0NWRkOWViMWFhM2NkMmM1NGM4Y18xNDQw_582fb18d-4d69-4b4a-8593-6095210b72ac">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="ic10c089cca4b439a8aac7cbb76b6909e_D20220228-20220228" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjc0ODVhNWM2YmQwYjRlOWI5Y2FmMWExNDRjZmRlN2Q1L3NlYzo3NDg1YTVjNmJkMGI0ZTliOWNhZjFhMTQ0Y2ZkZTdkNV8xL2ZyYWc6ZjJhN2RjYjI2Y2QzNDVkZDllYjFhYTNjZDJjNTRjOGMvdGV4dHJlZ2lvbjpmMmE3ZGNiMjZjZDM0NWRkOWViMWFhM2NkMmM1NGM4Y18xMDk5NTExNjI5MjQz_986ebfe3-f7a3-46c2-a9ea-feaacd89f2fd">February&#160;28, 2022</ix:nonNumeric>.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic10c089cca4b439a8aac7cbb76b6909e_D20220228-20220228" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjc0ODVhNWM2YmQwYjRlOWI5Y2FmMWExNDRjZmRlN2Q1L3NlYzo3NDg1YTVjNmJkMGI0ZTliOWNhZjFhMTQ0Y2ZkZTdkNV8xL2ZyYWc6ZjJhN2RjYjI2Y2QzNDVkZDllYjFhYTNjZDJjNTRjOGMvdGV4dHJlZ2lvbjpmMmE3ZGNiMjZjZDM0NWRkOWViMWFhM2NkMmM1NGM4Y18xNDQy_47b7dfed-ef7b-48ab-b007-95230ae449d5">PLIANT THERAPEUTICS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact name of Registrant as Specified in Its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________________________________</span></div><div style="margin-top:6pt;padding-left:269.85pt;padding-right:269.85pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic10c089cca4b439a8aac7cbb76b6909e_D20220228-20220228" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjc0ODVhNWM2YmQwYjRlOWI5Y2FmMWExNDRjZmRlN2Q1L3NlYzo3NDg1YTVjNmJkMGI0ZTliOWNhZjFhMTQ0Y2ZkZTdkNV8xL2ZyYWc6ZjJhN2RjYjI2Y2QzNDVkZDllYjFhYTNjZDJjNTRjOGMvdGFibGU6ZjgyNmY0MDMyM2U2NGJlNTk1Nzg1OGViZDg0Njc0MTAvdGFibGVyYW5nZTpmODI2ZjQwMzIzZTY0YmU1OTU3ODU4ZWJkODQ2NzQxMF8wLTAtMS0xLTI5MzAw_809c5e06-ad60-418b-88cb-ebc93455fa35">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic10c089cca4b439a8aac7cbb76b6909e_D20220228-20220228" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjc0ODVhNWM2YmQwYjRlOWI5Y2FmMWExNDRjZmRlN2Q1L3NlYzo3NDg1YTVjNmJkMGI0ZTliOWNhZjFhMTQ0Y2ZkZTdkNV8xL2ZyYWc6ZjJhN2RjYjI2Y2QzNDVkZDllYjFhYTNjZDJjNTRjOGMvdGFibGU6ZjgyNmY0MDMyM2U2NGJlNTk1Nzg1OGViZDg0Njc0MTAvdGFibGVyYW5nZTpmODI2ZjQwMzIzZTY0YmU1OTU3ODU4ZWJkODQ2NzQxMF8wLTEtMS0xLTI5MzAw_043d8995-b22c-479c-a8d9-0e402e0cd3e3">001-39303</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic10c089cca4b439a8aac7cbb76b6909e_D20220228-20220228" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjc0ODVhNWM2YmQwYjRlOWI5Y2FmMWExNDRjZmRlN2Q1L3NlYzo3NDg1YTVjNmJkMGI0ZTliOWNhZjFhMTQ0Y2ZkZTdkNV8xL2ZyYWc6ZjJhN2RjYjI2Y2QzNDVkZDllYjFhYTNjZDJjNTRjOGMvdGFibGU6ZjgyNmY0MDMyM2U2NGJlNTk1Nzg1OGViZDg0Njc0MTAvdGFibGVyYW5nZTpmODI2ZjQwMzIzZTY0YmU1OTU3ODU4ZWJkODQ2NzQxMF8wLTItMS0xLTI5MzAw_066d8818-0d2a-4a52-b6e0-fd13cec54d29">47-4272481</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(State or Other Jurisdiction</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of Incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(IRS Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Identification No.)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic10c089cca4b439a8aac7cbb76b6909e_D20220228-20220228" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjc0ODVhNWM2YmQwYjRlOWI5Y2FmMWExNDRjZmRlN2Q1L3NlYzo3NDg1YTVjNmJkMGI0ZTliOWNhZjFhMTQ0Y2ZkZTdkNV8xL2ZyYWc6ZjJhN2RjYjI2Y2QzNDVkZDllYjFhYTNjZDJjNTRjOGMvdGFibGU6ZjgyNmY0MDMyM2U2NGJlNTk1Nzg1OGViZDg0Njc0MTAvdGFibGVyYW5nZTpmODI2ZjQwMzIzZTY0YmU1OTU3ODU4ZWJkODQ2NzQxMF8zLTAtMS0xLTI5MzAwL3RleHRyZWdpb246MzE4OGVjYzViNjFlNDQ4MzgzYjhhNTM4MDQ4ZjY0MDBfNQ_ac474ece-8e2a-4b16-a8a7-f5fb40804d8d">260 Littlefield Avenue,</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic10c089cca4b439a8aac7cbb76b6909e_D20220228-20220228" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjc0ODVhNWM2YmQwYjRlOWI5Y2FmMWExNDRjZmRlN2Q1L3NlYzo3NDg1YTVjNmJkMGI0ZTliOWNhZjFhMTQ0Y2ZkZTdkNV8xL2ZyYWc6ZjJhN2RjYjI2Y2QzNDVkZDllYjFhYTNjZDJjNTRjOGMvdGFibGU6ZjgyNmY0MDMyM2U2NGJlNTk1Nzg1OGViZDg0Njc0MTAvdGFibGVyYW5nZTpmODI2ZjQwMzIzZTY0YmU1OTU3ODU4ZWJkODQ2NzQxMF8zLTAtMS0xLTI5MzAwL3RleHRyZWdpb246MzE4OGVjYzViNjFlNDQ4MzgzYjhhNTM4MDQ4ZjY0MDBfOA_a5767c87-f13f-4f5f-ba5e-1795c149aeb7">South San Francisco,</ix:nonNumeric> <ix:nonNumeric contextRef="ic10c089cca4b439a8aac7cbb76b6909e_D20220228-20220228" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjc0ODVhNWM2YmQwYjRlOWI5Y2FmMWExNDRjZmRlN2Q1L3NlYzo3NDg1YTVjNmJkMGI0ZTliOWNhZjFhMTQ0Y2ZkZTdkNV8xL2ZyYWc6ZjJhN2RjYjI2Y2QzNDVkZDllYjFhYTNjZDJjNTRjOGMvdGFibGU6ZjgyNmY0MDMyM2U2NGJlNTk1Nzg1OGViZDg0Njc0MTAvdGFibGVyYW5nZTpmODI2ZjQwMzIzZTY0YmU1OTU3ODU4ZWJkODQ2NzQxMF8zLTAtMS0xLTI5MzAwL3RleHRyZWdpb246MzE4OGVjYzViNjFlNDQ4MzgzYjhhNTM4MDQ4ZjY0MDBfMTE_a0866f46-a827-413c-a9f8-ff4878f593fc">CA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic10c089cca4b439a8aac7cbb76b6909e_D20220228-20220228" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjc0ODVhNWM2YmQwYjRlOWI5Y2FmMWExNDRjZmRlN2Q1L3NlYzo3NDg1YTVjNmJkMGI0ZTliOWNhZjFhMTQ0Y2ZkZTdkNV8xL2ZyYWc6ZjJhN2RjYjI2Y2QzNDVkZDllYjFhYTNjZDJjNTRjOGMvdGFibGU6ZjgyNmY0MDMyM2U2NGJlNTk1Nzg1OGViZDg0Njc0MTAvdGFibGVyYW5nZTpmODI2ZjQwMzIzZTY0YmU1OTU3ODU4ZWJkODQ2NzQxMF8zLTItMS0xLTI5MzAw_e6a4405c-030e-41a6-ae57-5d807069221f">94080</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s Telephone Number, Including Area Code: (<ix:nonNumeric contextRef="ic10c089cca4b439a8aac7cbb76b6909e_D20220228-20220228" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjc0ODVhNWM2YmQwYjRlOWI5Y2FmMWExNDRjZmRlN2Q1L3NlYzo3NDg1YTVjNmJkMGI0ZTliOWNhZjFhMTQ0Y2ZkZTdkNV8xL2ZyYWc6ZjJhN2RjYjI2Y2QzNDVkZDllYjFhYTNjZDJjNTRjOGMvdGV4dHJlZ2lvbjpmMmE3ZGNiMjZjZDM0NWRkOWViMWFhM2NkMmM1NGM4Y18xNDQz_ea19efce-e503-4e24-a41a-ba389c54c9e2">650</ix:nonNumeric>) <ix:nonNumeric contextRef="ic10c089cca4b439a8aac7cbb76b6909e_D20220228-20220228" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjc0ODVhNWM2YmQwYjRlOWI5Y2FmMWExNDRjZmRlN2Q1L3NlYzo3NDg1YTVjNmJkMGI0ZTliOWNhZjFhMTQ0Y2ZkZTdkNV8xL2ZyYWc6ZjJhN2RjYjI2Y2QzNDVkZDllYjFhYTNjZDJjNTRjOGMvdGV4dHJlZ2lvbjpmMmE3ZGNiMjZjZDM0NWRkOWViMWFhM2NkMmM1NGM4Y18xNDQ0_2173851a-dc5f-4e85-9c6e-3c075c7d15fa">481-6770</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________________________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic10c089cca4b439a8aac7cbb76b6909e_D20220228-20220228" name="dei:WrittenCommunications" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjc0ODVhNWM2YmQwYjRlOWI5Y2FmMWExNDRjZmRlN2Q1L3NlYzo3NDg1YTVjNmJkMGI0ZTliOWNhZjFhMTQ0Y2ZkZTdkNV8xL2ZyYWc6ZjJhN2RjYjI2Y2QzNDVkZDllYjFhYTNjZDJjNTRjOGMvdGFibGU6NTMxNTdmNzdjNDk0NDg4ZjgwZDUxNjQ4NDFlYjRkNjEvdGFibGVyYW5nZTo1MzE1N2Y3N2M0OTQ0ODhmODBkNTE2NDg0MWViNGQ2MV8wLTAtMS0xLTI5MzAw_4fdd0ca0-7ffc-4667-b5a3-6fdc09fe7432">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic10c089cca4b439a8aac7cbb76b6909e_D20220228-20220228" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjc0ODVhNWM2YmQwYjRlOWI5Y2FmMWExNDRjZmRlN2Q1L3NlYzo3NDg1YTVjNmJkMGI0ZTliOWNhZjFhMTQ0Y2ZkZTdkNV8xL2ZyYWc6ZjJhN2RjYjI2Y2QzNDVkZDllYjFhYTNjZDJjNTRjOGMvdGFibGU6NTMxNTdmNzdjNDk0NDg4ZjgwZDUxNjQ4NDFlYjRkNjEvdGFibGVyYW5nZTo1MzE1N2Y3N2M0OTQ0ODhmODBkNTE2NDg0MWViNGQ2MV8yLTAtMS0xLTI5MzAw_2107c958-11ff-44c3-b42e-566a21b195c5">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic10c089cca4b439a8aac7cbb76b6909e_D20220228-20220228" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjc0ODVhNWM2YmQwYjRlOWI5Y2FmMWExNDRjZmRlN2Q1L3NlYzo3NDg1YTVjNmJkMGI0ZTliOWNhZjFhMTQ0Y2ZkZTdkNV8xL2ZyYWc6ZjJhN2RjYjI2Y2QzNDVkZDllYjFhYTNjZDJjNTRjOGMvdGFibGU6NTMxNTdmNzdjNDk0NDg4ZjgwZDUxNjQ4NDFlYjRkNjEvdGFibGVyYW5nZTo1MzE1N2Y3N2M0OTQ0ODhmODBkNTE2NDg0MWViNGQ2MV80LTAtMS0xLTI5MzAw_9d5c1b21-18fb-4f48-851c-15b712119a8f">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic10c089cca4b439a8aac7cbb76b6909e_D20220228-20220228" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjc0ODVhNWM2YmQwYjRlOWI5Y2FmMWExNDRjZmRlN2Q1L3NlYzo3NDg1YTVjNmJkMGI0ZTliOWNhZjFhMTQ0Y2ZkZTdkNV8xL2ZyYWc6ZjJhN2RjYjI2Y2QzNDVkZDllYjFhYTNjZDJjNTRjOGMvdGFibGU6NTMxNTdmNzdjNDk0NDg4ZjgwZDUxNjQ4NDFlYjRkNjEvdGFibGVyYW5nZTo1MzE1N2Y3N2M0OTQ0ODhmODBkNTE2NDg0MWViNGQ2MV82LTAtMS0xLTI5MzAw_66c0ee75-d8e6-47fb-b14d-b6bacc9cedbb">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.476%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Trading</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Symbol(s)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic10c089cca4b439a8aac7cbb76b6909e_D20220228-20220228" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjc0ODVhNWM2YmQwYjRlOWI5Y2FmMWExNDRjZmRlN2Q1L3NlYzo3NDg1YTVjNmJkMGI0ZTliOWNhZjFhMTQ0Y2ZkZTdkNV8xL2ZyYWc6ZjJhN2RjYjI2Y2QzNDVkZDllYjFhYTNjZDJjNTRjOGMvdGFibGU6NTJjMTkyMzllMzk1NDFjY2I0N2NlYWQzYTMyMzc0NzkvdGFibGVyYW5nZTo1MmMxOTIzOWUzOTU0MWNjYjQ3Y2VhZDNhMzIzNzQ3OV8xLTAtMS0xLTI5MzAw_087390d2-e842-4cef-99a5-b73739e49cb8">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic10c089cca4b439a8aac7cbb76b6909e_D20220228-20220228" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjc0ODVhNWM2YmQwYjRlOWI5Y2FmMWExNDRjZmRlN2Q1L3NlYzo3NDg1YTVjNmJkMGI0ZTliOWNhZjFhMTQ0Y2ZkZTdkNV8xL2ZyYWc6ZjJhN2RjYjI2Y2QzNDVkZDllYjFhYTNjZDJjNTRjOGMvdGFibGU6NTJjMTkyMzllMzk1NDFjY2I0N2NlYWQzYTMyMzc0NzkvdGFibGVyYW5nZTo1MmMxOTIzOWUzOTU0MWNjYjQ3Y2VhZDNhMzIzNzQ3OV8xLTItMS0xLTI5MzAw_271a6966-964a-46a4-a885-16db83d17304">PLRX</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic10c089cca4b439a8aac7cbb76b6909e_D20220228-20220228" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjc0ODVhNWM2YmQwYjRlOWI5Y2FmMWExNDRjZmRlN2Q1L3NlYzo3NDg1YTVjNmJkMGI0ZTliOWNhZjFhMTQ0Y2ZkZTdkNV8xL2ZyYWc6ZjJhN2RjYjI2Y2QzNDVkZDllYjFhYTNjZDJjNTRjOGMvdGFibGU6NTJjMTkyMzllMzk1NDFjY2I0N2NlYWQzYTMyMzc0NzkvdGFibGVyYW5nZTo1MmMxOTIzOWUzOTU0MWNjYjQ3Y2VhZDNhMzIzNzQ3OV8xLTQtMS0xLTI5MzAw_6cfe474e-de62-421d-bfbd-16bffd3c207b">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160;<ix:nonNumeric contextRef="ic10c089cca4b439a8aac7cbb76b6909e_D20220228-20220228" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjc0ODVhNWM2YmQwYjRlOWI5Y2FmMWExNDRjZmRlN2Q1L3NlYzo3NDg1YTVjNmJkMGI0ZTliOWNhZjFhMTQ0Y2ZkZTdkNV8xL2ZyYWc6ZjJhN2RjYjI2Y2QzNDVkZDllYjFhYTNjZDJjNTRjOGMvdGV4dHJlZ2lvbjpmMmE3ZGNiMjZjZDM0NWRkOWViMWFhM2NkMmM1NGM4Y18xNDQ1_850a1f70-dba2-40fc-8e8c-57251af5a0c7">&#9744;</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#9744;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i7485a5c6bd0b4e9b9caf1a144cfde7d5_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02&#160;&#160;&#160;&#160;Results of Operations and Financial Condition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:10pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;28, 2022, Pliant Therapeutics, Inc. (the "Company") issued a press release announcing the Company&#8217;s financial results for the fourth quarter and year ended December&#160;31, 2021. A copy of this press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.</span></div><div style="margin-top:10pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in this Current Report on Form 8-K including the exhibits furnished herewith shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (as amended, the "Exchange Act") or otherwise subject to the liabilities of that Section, and shall not be or be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.</span></div><div id="i7485a5c6bd0b4e9b9caf1a144cfde7d5_13"></div><div style="-sec-extract:summary;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01 &#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits.&#160;</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.652%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">No.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a4q2021exhibit991.htm">Press Release issued by the Company dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a4q2021exhibit991.htm">February 28</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a4q2021exhibit991.htm">,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a4q2021exhibit991.htm"> 2022</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a4q2021exhibit991.htm">.</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i7485a5c6bd0b4e9b9caf1a144cfde7d5_16"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.459%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.460%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PLIANT THERAPEUTICS, INC.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: February&#160;28, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;Keith Cummings</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Keith Cummings, M.D., MBA</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a4q2021exhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ibee360b2466a40f48a89349dc22b029b_1"></div><div style="min-height:45pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="margin-top:12pt;text-align:center"><img alt="image_0.jpg" src="image_0.jpg" style="height:80px;margin-bottom:5pt;vertical-align:text-bottom;width:160px"></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Pliant Therapeutics Provides Corporate Update and </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reports Fourth Quarter and Full Year 2021 Financial Results</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SOUTH SAN FRANCISCO, CA., February 28, 2022 - Pliant Therapeutics, Inc. (Nasdaq&#58; PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported fourth quarter and full year 2021 financial results.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;In 2021 strong execution drove significant advancement of our pipeline. The achievement of strategic milestones and positive data further de-risked our ongoing and potential future clinical programs,&#8221; said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant Therapeutics. &#8220;We are building on this momentum in 2022 with significant data readouts anticipated in our lead programs of idiopathic pulmonary fibrosis and primary sclerosing cholangitis, as well as planned investigational new drug applications in our oncology and muscular dystrophy programs.&#8221;</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fourth Quarter and Recent Highlights</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.5pt">Results from expanded PLN-74809 Phase 1b proof-of-mechanism trial demonstrated clear evidence of on-target biological activity in the lungs of healthy participants. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earlier today, the Company announced that positive data from an expanded PLN-74809 Phase 1b proof-of-mechanism trial demonstrated clear evidence of on-target biological activity in the lungs of 36 healthy participants. Results demonstrated that PLN-74809 inhibited TGF-&#946; activation by up to 92% and 76% at 6- and 24-hours, respectively, following seven days of once-daily dosing. At all dose levels, PLN-74809 demonstrated durable pSmad suppression relative to placebo at 6 hours and 24 hours. PLN-74809 was well tolerated with mostly mild adverse events, and no severe adverse events. </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Enrollment was completed in the PLN-74809 Phase 2a INTEGRIS-IPF trial in idiopathic pulmonary fibrosis.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> INTEGRIS-IPF is a 12-week randomized, dose-ranging, double-blind, placebo-controlled trial evaluating the safety, tolerability and pharmacokinetics of PLN-74809 at doses of 40, 80 or 160 mg in approximately 84 IPF patients. Exploratory endpoints include quantitative lung fibrosis (QLF) imaging, pulmonary function tests as well as select biomarkers. Topline data is anticipated mid-2022.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">The U.S. Food and Drug Administration (FDA) authorized the evaluation of long-term treatment with PLN-74809 in patients with IPF.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The FDA has authorized evaluation of long-term dosing of PLN-74809 up to 320 mg daily in patients with IPF.  This authorization will facilitate longer-term pivotal trials in IPF. PLN-74809 has been administered to over 450 study participants, including healthy volunteers and patients, with no drug-related serious adverse events or severe adverse advents reported to date. </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Independent Data Safety Monitoring Board (DSMB) recommended INTEGRIS-IPF Phase 2a Trial continue without modifications. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the full enrollment of the INTEGRIS-IPF Phase 2a trial, on February 17, 2022, the DSMB recommended the INTEGRIS-IPF trial continue without modification. This review included all patients enrolled in all dose cohorts of the trial. To date, no safety concerns have been identified by the DSMB.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Commenced enrollment of a Phase 2a trial of PLN-74809 at a dose of 320 mg in patients with IPF. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company began enrollment in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a randomized, double-blind, placebo-controlled trial evaluating PLN-74809 at doses of 320 mg administered daily over at least six months, and up to 48 weeks, in approximately 28 patients with IPF. The primary endpoint is the evaluation of PLN-74809 safety and tolerability and the secondary endpoint is the assessment of  pharmacokinetics. Exploratory endpoints will measure QLF </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">imaging and pulmonary function tests as well as select biomarkers</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> over 6 months of treatment. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">PLN-74809 Phase 2a trial in primary sclerosing cholangitis (PSC) enrollment on track to be completed mid-2022.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> INTEGRIS-PSC is a 12-week randomized, dose-ranging, double-blind, placebo-controlled trial evaluating the safety, tolerability, and pharmacokinetics of PLN-74809 at doses of 40, 80 or 160 mg in approximately 84 PSC </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-top:10pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patients. Exploratory endpoints include fibrosis biomarkers such as Pro-C3 and ELF, changes in ALP and liver imaging.  Topline data is expected in late 2022 or early 2023.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Oncology and muscular dystrophy programs progressing through Investigational New Drug (IND) enabling studies.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both programs on track with IND application submissions planned by the end of 2022. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> COVID-19 Preparedness</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to develop and maintain policies and procedures to enable us to operate safely and productively during the COVID-19 pandemic. The Company has experienced delays in clinical trial operations which have impacted and may further impact the expected timing of data readouts. The Company is working closely with clinical sites to continue site initiation and operation activities in compliance with study protocols while observing government and institutional guidelines. The Company intends to provide more specific guidance regarding clinical trial progress and the timing of data readouts as the long-term impacts of the pandemic become better understood.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fourth Quarter 2021 Financial Results</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Research and development expenses were $18.8 million, as compared to $17.9 million for the prior-year quarter. The increase was due primarily to employee related expenses and higher costs related to the advancement of several programs and ongoing Phase 1&#47;2 clinical trials.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">General and administrative expenses were $7.8 million, as compared to $5.6 million for the prior-year quarter. The increase was due to higher personnel-related and professional services expenses.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net loss of $24.5 million, as compared to $19.0 million for the prior-year quarter. The increase is due an overall increase in operating expense coupled with a decrease in revenues generated from our license and collaboration agreement.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As of December&#160;31, 2021, the Company had cash, cash equivalents and short-term investments of $200.6 million. The Company believes it has sufficient funds to meet its operating and capital requirements into the second half of 2023.</font></div><div style="margin-top:10pt"><font style="color:#000d1b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Pliant Therapeutics, Inc.</font></div><div style="margin-top:10pt"><font style="background-color:#ffffff;color:#000d1b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small molecule dual selective inhibitor of &#945;</font><font style="color:#000d1b;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">v</font><font style="background-color:#ffffff;color:#000d1b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#223;</font><font style="color:#000d1b;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">6 </font><font style="background-color:#ffffff;color:#000d1b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and &#945;</font><font style="color:#000d1b;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">v</font><font style="background-color:#ffffff;color:#000d1b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#223;</font><font style="color:#000d1b;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">1 </font><font style="background-color:#ffffff;color:#000d1b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently conducting Phase 2a trials of PLN-74809 in the lead indications of IPF and PSC. Pliant has also developed PLN-1474, a small molecule selective inhibitor of &#945;</font><font style="color:#000d1b;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">v</font><font style="background-color:#ffffff;color:#000d1b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#223;</font><font style="color:#000d1b;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">1 </font><font style="background-color:#ffffff;color:#000d1b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the treatment of nonalcoholic steatohepatitis, or NASH with liver fibrosis, which Pliant has transferred to Novartis pursuant to our development partnership. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies. For additional information about Pliant Therapeutics, visit </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">www.pliantrx.com</font><font style="background-color:#ffffff;color:#000d1b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and follow us on </font><font style="background-color:#ffffff;color:#143fdc;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Twitter</font><font style="background-color:#ffffff;color:#000d1b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="background-color:#ffffff;color:#143fdc;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LinkedIn</font><font style="background-color:#ffffff;color:#000d1b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="background-color:#ffffff;color:#143fdc;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facebook</font><font style="background-color:#ffffff;color:#000d1b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </font><font style="background-color:#ffffff;color:#143fdc;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">YouTube</font><font style="background-color:#ffffff;color:#000d1b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Forward-Looking Statements</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Statements contained in this press release regarding matters that are not historical facts are &#34;forward-looking statements&#34; within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as &#34;may,&#34; &#34;will,&#34; &#34;expect,&#34; &#34;anticipate,&#34; &#34;estimate,&#34; &#34;intend,&#34; and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those regarding the de-risking of our ongoing and potential future clinical programs&#59; planned INDs in our oncology and muscular dystrophy programs&#59; anticipated progress of our clinical trials and timing of regulatory, enrollment and data disclosures&#59; the efficacy and safety profile of our product candidates&#59; our expectations regarding our interactions with regulators, including the FDA&#59; and anticipated progress of our pre-clinical programs, including timing expectations for regulatory filings. Because such statements deal with future events and are based on our current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Pliant Therapeutics could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including those related to the development and commercialization of our product candidates, including any delays in our ongoing or planned preclinical or clinical trials, the impact of the ongoing COVID-19 pandemic on our business, operations, clinical supply and plans, our reliance on third parties for critical aspects of our development operations, the risks inherent in the drug development process, the risks regarding the accuracy of our estimates of expenses and timing of development, our capital requirements and the need for additional financing, and our ability to obtain and maintain intellectual property protection for our product </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">candidates. These and additional risks are discussed in the sections titled &#34;Risk Factors&#34; and &#34;Management's Discussion and Analysis of Financial Condition and Results of Operations&#34; in our Annual Report on Form 10-K filed for the year ended December 31, 2020 with the SEC on March 16, 2021, as updated by our Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed with the SEC on November 9, 2021 filed for the year ended December 31, 2020 with the SEC on March 16, 2021, as updated by our Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed with the SEC on November 9, 2021, and our subsequent filings with the SEC, which are available on the SEC's website at www.sec.gov. Unless otherwise noted, Pliant is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.</font></div><div style="margin-top:10pt"><font><br></font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investor and Media Contact&#58;</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Christopher Keenan</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vice President, Investor Relations and Corporate Communications</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pliant Therapeutics, Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ir&#64;pliantrx.com</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><div id="ibee360b2466a40f48a89349dc22b029b_4"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pliant Therapeutics, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Statements of Operations</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except number of shares and per share amounts)</font></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.590%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.794%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Three Months Ended December 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Year Ended December 31,</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">2021</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">2021</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Revenue</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">1,999&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">4,465&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">7,572&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">41,817&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Operating expenses&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Research and development</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(18,752)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(17,854)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(66,193)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">General and administrative</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(7,846)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(5,627)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(27,558)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(17,269)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Total operating expenses</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(26,598)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(23,481)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(27,558)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(83,462)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Loss from operations</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(24,599)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(19,016)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(19,986)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(41,645)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Interest and other income (expense), net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">68&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(11)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">272&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">112&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Net income loss</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(24,531)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(19,027)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(19,714)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(41,533)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Less&#58; Undistributed earnings to preferred shareholders</font></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Net loss attributable to common stockholders</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(24,531)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(19,027)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(19,714)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(41,533)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Net loss per share, attributable to common stockholders&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Basic</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(0.68)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(0.54)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(2.71)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1.95)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Diluted</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(0.68)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(0.54)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(2.71)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1.95)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Shares used in computing net loss per share attributable to common stockholders&#58;</font></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Basic</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">36,022,148&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">35,495,414&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">35,846,421&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">21,344,236&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Diluted</font></td><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">36,022,148&#160;</font></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">35,495,414&#160;</font></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">35,846,421&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">21,344,236&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><div id="ibee360b2466a40f48a89349dc22b029b_7"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pliant Therapeutics, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Balance Sheets</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</font></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.771%"><tr><td style="width:1.0%"></td><td style="width:67.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.083%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">December 31,<br>2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">December 31,<br>2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">51,665&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50,882&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Short-term investments</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">148,931&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">226,012&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts receivable</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,998&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,279&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tax credit receivable</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">83&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">83&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets (Note 5)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,764&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,498&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total current assets</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">209,441&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">290,754&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Property and equipment, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,606&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,321&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,330&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other non-current assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">838&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">451&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total assets</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">221,215&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">295,526&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Liabilities and stockholders&#8217; equity</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts payable</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,971&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,023&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accrued liabilities (Note 6)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,991&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,576&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities, current</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,869&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total current liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,831&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,599&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities, non-current</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,325&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other long-term liabilities (Note 6)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">866&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total liabilities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,156&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,465&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stockholders&#8217; equity (deficit)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Common stock</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additional paid-in capital</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">414,348&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">400,918&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated deficit</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(215,091)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(117,828)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(201)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(32)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total stockholders&#8217; equity</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">199,059&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">283,061&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total liabilities and stockholders&#8217; equity</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">221,215&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">295,526&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>plrx-20220228.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:2ec302b2-b7ae-47b4-961d-2f7a10122ea7,g:5288333c-f784-4bbc-96a0-5f543685bee2-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:plrx="http://www.pliantrx.com/20220228" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.pliantrx.com/20220228">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="plrx-20220228_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="plrx-20220228_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.pliantrx.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>plrx-20220228_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:2ec302b2-b7ae-47b4-961d-2f7a10122ea7,g:5288333c-f784-4bbc-96a0-5f543685bee2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_DocumentType_ca57b6f6-9a5e-4e0a-a124-a40c7d30c4a2_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_88b0d677-058a-4a3e-83e4-eeadfcfdcc96_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_c8bfc8e5-e606-4636-813d-b136f13c7441_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_98265e9f-bd11-4cb2-8a2a-6b49a3adf169_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_f08359c5-96b1-4c9d-89f7-9f954bef8ba8_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_b5158c50-31f9-4984-a421-f4c9f09c733b_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_d7772551-f6bc-4112-8ce9-85078b8a07b9_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_079492f6-9a09-446a-acc6-96925d17e34e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_16984d65-68e4-4945-b3f2-883aadd6f69a_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_ba97307d-f111-4ab3-a68a-013e681fe2e5_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_51c47719-dc54-41c7-a3c3-0179e5d95f5a_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_34ed55f7-1789-4121-b8e6-91da4337a905_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_f8801529-cb88-41c8-8931-f10b37754b6c_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_ebb85c59-ac2e-4e82-9ca8-92bcf179e0e2_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_5af3c2fb-83ae-45c6-95ab-687cbc611308_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_ab1ffc2e-5aca-480b-ad8e-0025ce100898_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_20fea758-e9ab-4b1e-a46b-397417a2039e_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_0203970d-3e0f-45e8-8849-018784dc0e30_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_cafdce7f-20b4-472c-b887-35b6f726f4c4_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_90e8db7e-2bb3-4f1c-9543-34b91c664213_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_ef850a0a-d317-4421-9515-5749a793eb39_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_339d47fe-d2e9-4105-bfc8-4aacb9db4838_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>plrx-20220228_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:2ec302b2-b7ae-47b4-961d-2f7a10122ea7,g:5288333c-f784-4bbc-96a0-5f543685bee2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.pliantrx.com/role/Cover" xlink:type="simple" xlink:href="plrx-20220228.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_8200019a-68d4-4ab6-a63e-1f29a9b9a585" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_03f61a5e-4b70-41d6-b421-dd0b2e0d60b1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8200019a-68d4-4ab6-a63e-1f29a9b9a585" xlink:to="loc_dei_DocumentType_03f61a5e-4b70-41d6-b421-dd0b2e0d60b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_d059d668-3520-40ef-92b5-9babcf037b1f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8200019a-68d4-4ab6-a63e-1f29a9b9a585" xlink:to="loc_dei_DocumentPeriodEndDate_d059d668-3520-40ef-92b5-9babcf037b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_2d55e5c0-9f37-48f3-8333-7c9c5be3bb07" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8200019a-68d4-4ab6-a63e-1f29a9b9a585" xlink:to="loc_dei_EntityRegistrantName_2d55e5c0-9f37-48f3-8333-7c9c5be3bb07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_f29904b5-3463-4822-9357-c8bb679255ad" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8200019a-68d4-4ab6-a63e-1f29a9b9a585" xlink:to="loc_dei_EntityIncorporationStateCountryCode_f29904b5-3463-4822-9357-c8bb679255ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_545c534f-040d-4df8-a0aa-ef24502e2d91" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8200019a-68d4-4ab6-a63e-1f29a9b9a585" xlink:to="loc_dei_EntityFileNumber_545c534f-040d-4df8-a0aa-ef24502e2d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_1e99f6d4-cf0a-4ff6-9b00-5bebafbba8ac" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8200019a-68d4-4ab6-a63e-1f29a9b9a585" xlink:to="loc_dei_EntityTaxIdentificationNumber_1e99f6d4-cf0a-4ff6-9b00-5bebafbba8ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_21d12e9b-c639-4c7b-a37f-7e5923fef404" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8200019a-68d4-4ab6-a63e-1f29a9b9a585" xlink:to="loc_dei_EntityAddressAddressLine1_21d12e9b-c639-4c7b-a37f-7e5923fef404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_9b56b267-e9cd-4563-b142-0eb91ff2391b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8200019a-68d4-4ab6-a63e-1f29a9b9a585" xlink:to="loc_dei_EntityAddressCityOrTown_9b56b267-e9cd-4563-b142-0eb91ff2391b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_c185c17a-df9c-4187-863a-9f82ee677680" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8200019a-68d4-4ab6-a63e-1f29a9b9a585" xlink:to="loc_dei_EntityAddressStateOrProvince_c185c17a-df9c-4187-863a-9f82ee677680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_dc93ca8b-5098-47d4-b33d-2115ad9993a6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8200019a-68d4-4ab6-a63e-1f29a9b9a585" xlink:to="loc_dei_EntityAddressPostalZipCode_dc93ca8b-5098-47d4-b33d-2115ad9993a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_eb2c9ed6-3bf0-4404-93a6-8e86603aa8d5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8200019a-68d4-4ab6-a63e-1f29a9b9a585" xlink:to="loc_dei_CityAreaCode_eb2c9ed6-3bf0-4404-93a6-8e86603aa8d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_39afa448-2b41-4faa-8d75-908339c33451" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8200019a-68d4-4ab6-a63e-1f29a9b9a585" xlink:to="loc_dei_LocalPhoneNumber_39afa448-2b41-4faa-8d75-908339c33451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_5383dbef-0ab4-4098-ba49-2b7b959ef2d4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8200019a-68d4-4ab6-a63e-1f29a9b9a585" xlink:to="loc_dei_WrittenCommunications_5383dbef-0ab4-4098-ba49-2b7b959ef2d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_77b3ce30-92e8-4277-a9fc-7199a1c5215c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8200019a-68d4-4ab6-a63e-1f29a9b9a585" xlink:to="loc_dei_SolicitingMaterial_77b3ce30-92e8-4277-a9fc-7199a1c5215c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_829ceaa8-fe80-46c2-b847-54b21a3b7028" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8200019a-68d4-4ab6-a63e-1f29a9b9a585" xlink:to="loc_dei_PreCommencementTenderOffer_829ceaa8-fe80-46c2-b847-54b21a3b7028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_7d93c371-d8c0-4f65-b49c-f9a9fe096697" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8200019a-68d4-4ab6-a63e-1f29a9b9a585" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_7d93c371-d8c0-4f65-b49c-f9a9fe096697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_d38152a9-27a4-4918-9727-2ede14be713c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8200019a-68d4-4ab6-a63e-1f29a9b9a585" xlink:to="loc_dei_Security12bTitle_d38152a9-27a4-4918-9727-2ede14be713c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_0c030430-0df9-4745-be91-8ec2770b7eb0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8200019a-68d4-4ab6-a63e-1f29a9b9a585" xlink:to="loc_dei_TradingSymbol_0c030430-0df9-4745-be91-8ec2770b7eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_570b7ab9-e3de-4a29-af51-12532a9da4f5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8200019a-68d4-4ab6-a63e-1f29a9b9a585" xlink:to="loc_dei_SecurityExchangeName_570b7ab9-e3de-4a29-af51-12532a9da4f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_aace8776-f51d-499d-aed0-6ea4a6e117a2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8200019a-68d4-4ab6-a63e-1f29a9b9a585" xlink:to="loc_dei_EntityEmergingGrowthCompany_aace8776-f51d-499d-aed0-6ea4a6e117a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_6ab1752c-8f1a-46b2-a5fd-74d85dedb84a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8200019a-68d4-4ab6-a63e-1f29a9b9a585" xlink:to="loc_dei_EntityCentralIndexKey_6ab1752c-8f1a-46b2-a5fd-74d85dedb84a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_c504df3b-2818-4ced-8b33-3bd5a3fd51d5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8200019a-68d4-4ab6-a63e-1f29a9b9a585" xlink:to="loc_dei_AmendmentFlag_c504df3b-2818-4ced-8b33-3bd5a3fd51d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $: C0# 2(  A$! Q$!_\0
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MS&'@E213W1@:)TY0^) FF2T445 PHHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=YKD<,8W6&DCRE/]^0<AO?@TIR44V_Z_K;[RX>]9+^OZW^XZ7PGHB:)HT<9
M,TI,LK=]S<D?F:W:**\B<G.3D^IZ,8J*L@HHHJ2@HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *IZG>?8K&24<R8Q&O\ >;L*N5SFH7(N;V20_-;V?5?[TG48]:UI
M0YI&5:IR1\S+^RC:ME(Q)8_:+PMU ;E5_.FE7N09USY]\=D(_BBB/!/YBK'D
M&11;2$EIB9KECP40\J*,M,K7" A[G]U:C',<9ZG'UKNO_7]?U9'FV3_K^O\
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M 'O-%%>=?%WQ7K'A/1K&XT>(O)-,R28[ +F@#T6BOEK_ (7/XW_YXO\ D?\
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M^F_WU_G7G_[.?_(P7W_7 _S% 'TC1110 5'/,EO \TAPB#)-25P_Q9UL:+X
MU$K)LFN(S'$PZAJ /G&0W'CGXI\@%GN0"",Y1&_PJQ\3-'/@[XA/+8CR@S>?
M%Z+S70_ #1?[1\6W&K2?-]E4@Y[E@:Z7]HK1 UG8ZPB$N'\IB!T&": /8?#&
MIIJ_ARQO(V#!HE!(]0!FM>O(O@!KBWWA!],+9>S;N?[Q)KUV@ I#T-+2'H:
M/C3XJ?\ )0]2_P!Y?Y5V?P+\=-I.L'0+^7%K<G$(/\+G^F!7*?$8 _%2Y##(
M,\>1Z]*O_$3PC-X9FTW7=-C\NUN(U?<O\,G)- 'UH"" 1T-+7"?"SQFOB[PM
M$\K+]M@ 290<X]/T%=W0!S'Q!_Y$G4O^N+?R-?.WP*_Y'R/Z"OHGX@_\B3J7
M_7%OY&OG;X%?\CY']!0!]85!=65K?($NK>.90<@2+D"IZ* ,S_A'=&_Z!=I_
MWZ%<)\7M&TRU^'>I2V]A;Q2!.&2, CD5Z=7G_P 9O^2;:G_US_J* /&_@'96
MM[XME2ZMXYE\ESAUR.@KZ1_X1W1O^@7:?]^A7SK^SS_R.,W_ %Q?^0KZ=H H
MP:+IEK,)K>PMXI!P&2, U>HHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ KD?B#XF7P_H#I$<W=T?)B0=?FXS^&:ZQW6-&=R%51DDU\]^*_$)
MU[Q)<:@26M;4F"U0]"[<9_ UU82C[2=WLB9.R*<)2VV+.=\-B/M%UDY\V7H5
MJ54F:,6S/MFN3]INW/\ "B<A?Q6J*;4VQ7/S16W^E7K?WV/!7^5/W2R*(7?_
M $BZ/G3L3RD:?P_BM>QK_7]?/[C!I,OBX>=6\H%)M1/V>W_Z90CYE;],5(;M
M$+7<"9CB_P!%LT]2_#-^#5G_ &OS"[VXVR77^BVBGJD8Y#?SIQN$A8S1#,-L
M/(MD_O._5OP:BW]?U]WWF3BUL:$;QQ'$C!X--7SI0?\ EK.?E8>_7-.0R86S
M=SOD/VJ]<^B<JOXK6<KHGEQ3'?%9_P"DW/\ MR'@K_*G+-*RBW=]TMRWGW+G
MJJ)_#^*T^7^OZ^_[B&:+3-<*WE92XU%O*CS_ ,LH1\RGV]*4W !>[B7Y$_T6
MS3UW\,WX&LYKLR&22'B6Y_<6X/\ RSC'(/Y4JW:B3=%\T< \BW3^\S]_P--1
M=OZ_KR^\SE:_]?UYG5^%]*.L:Y;67WK/3R)IS_?E/#"O8E 50HZ 8%<YX)T3
M^QM B$@_TF?][*3UR>M=)7B8JK[2IILCOH4^2'F%%%%<QL%%%% &3XF_Y%N^
M_P"N1KY*^'/_ "4:R_Z^/_9J^M?$W_(MWW_7(U\E?#G_ )*-9?\ 7Q_[-0!]
MET444 -D_P!6WT-?&WC%2_Q7U!1U-X /R%?6OB'7;'0-(N+N]G6-50X!/).*
M^3-!6X\8?%&&Y2//G70E<#LH(% 'UWHH*Z'8 ]1;H/\ QT5>J."(0V\<0Z(H
M4?A4E 'Q3XC_ .2BW'_7]_[4K[-L/^/"#_<%?&7B/_DHMQ_U_?\ M2OLVP_X
M\(/]P4 6:*** "BBB@#R[X\?\D^F_P!]?YUY_P#LY_\ (P7W_7 _S%>@?'C_
M ))]-_OK_.O/_P!G/_D8+[_K@?YB@#Z1HHHH *^>?VB=?W75EHB$X4><Q![\
MC%?0<L@BA>1ONHI8_A7QWX[O9_%WQ)NX83OWW!B@Y[=J /<O@/HBZ?X)%\T>
MR:Z<[LCD@'BNE^)VC'6O >IP(NZ982T8Q_%6[X>L$TS0+*U10NR%<@>N!FM"
M2-98VC<95A@@T ?+7P-ULZ/XY;3ICMCG#!\_W@,"OJBOC#6[2;PA\2602E3%
M=K*6_P!DMG^5?86DZA'JNDVM_$08YXPZD>AH NTAZ&EI#T- 'Q[\1?\ DJMS
M_P!=X_Z5])7?ANV\5?#F#3+A1F2U 1R/NGU%?-OQ%_Y*K<_]=X_Z5]7^&_\
MD6]/_P"N"T ?+'@S7+_X:>/S:W<;I"TOE2QD\8)P&_ <U]:VMS%>6L=Q X>*
M1=RL.XKQ'X\^!C<6B>)+"$F6(A9U0<MGO^ %6_@3XZ&IZ:WA^]E/VFV7,18]
M5Z "@#T+X@_\B3J7_7%OY&OG;X%?\CY']!7T3\0?^1)U+_KBW\C7SM\"O^1\
MC^@H ^L**** "O/_ (S?\DVU/_KG_45Z!7G_ ,9O^2;:G_US_J* /(OV>?\
MD<9O^N+_ ,A7T[7S%^SS_P CC-_UQ?\ D*^G: "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ***@O+J.RLY;F9@J1H6)/L,T+4#@_BKXE?3-%&F
M69S=WO[OY3R@]?TKQB.2.(@_>B@& /[TC=#^!JSXD\0RZ]X@NM2+;DW%+;GH
MO:LH2*, D%8\GKU8\C]:^AP]#V5-1ZF#=W<T?,^589SE0?/NB.^>-M-:9I%.
M<^=<$,S _=1>WXBLXSY $A'SMOD/J/2FBX:9W,0+2.0/EYP/2MN41H-= L\L
M74KY%OC^$#G-/2YCC8$',-NI5 ?XG;D'\#44&D:Q<R+Y&DW;\81EB) ]ZWK+
MX:>*;Y8]MM%$@Y_>L5/\JF4H1^)@D8GG9"QRME=WG3D'[Q/:AKTLC;F&^<@L
M1QM4<8_*N]M/@K?SK_INI&')R?*(/\ZZ73_@YHEJ/])N);L]_,4#^582QE"/
M6X.FWT/'1>$AG3+';Y<>T?= [UV?PYT)M;UU)Y8V^Q6/4,I&7/(->J67@7PW
M8!?(TN$,._/^-;L%M#;)LAC5%]%%<M;,$XN,%N*.'U5R4<# HHHKRSI"BBB@
M HHHH R?$W_(MWW_ %R-?$]C->P:UYFGEA<K(=FWKG-?;'B;_D6[[_KD:^2O
MAR ?B+9 @$>?W_WJ -3^W_B/_>N_R;_&C^W_ (C_ -Z[_)O\:^M/)B_YY)_W
MR*/)B_YY)_WR* /D,^&/B#XLF"3Q7DR,>1)(=H_ FO<_A?\ "V'P9 ;V]99M
M1D'4#A!W%>E!%7[J@?04Z@ HHHH ^*?$?_)1;C_K^_\ :E?9MA_QX0?[@KXR
M\1_\E%N/^O[_ -J5]FV'_'A!_N"@"S1110 4444 >7?'C_DGTW^^O\Z\_P#V
M<_\ D8+[_K@?YBO0/CQ_R3Z;_?7^=>?_ +.?_(P7W_7 _P Q0!](T444 <QX
M_P!;30/!M_>.V,QF,?5@17S5\'=%?7/B%:3N2PM'$[D\YYQ7I'[1&OO!IUEH
M\1!6X):7GD8P11^SMHH33+W5W0AV?RE)'4<&@#W,   #H*6BB@#YG_:$T1;/
MQ%:ZFB?\?:D.1[8%>F_!'71JW@6&!F^>S/D@>P%,^.6B-JG@26>*/=/;NI7V
M7/->:_L^:Z;3Q'<Z9+)B*>,>6N>KYH ^F*0]#2TAZ&@#X]^(O_)5;G_KO'_2
MOJ_PW_R+>G_]<%KY0^(O_)5;G_KO'_2OJ_PW_P BWI__ %P6@"[>VD5_936L
MZAHY4*,#Z$8KY)\3:9?_  Q^(JSVK,D:R>;"0."IS@'UKZ]KSWXM>"%\6^&)
M'@0&^M09(L#[QZ8H =K'B"U\3?"FXU*U<,LEN<\]#M.:\/\ @5_R/D?T%4/"
M/C-]"T?5_#U^6\B>-PN?X& ( 'XFK_P*_P"1\C^@H ^L**** "O/_C-_R3;4
M_P#KG_45Z!7G_P 9O^2;:G_US_J* /(OV>?^1QF_ZXO_ "%?3M?,7[//_(XS
M?]<7_D*^G: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\]^*'
M]N:CIB:1HEH\S3,#*ZL!M /3\:]"I,#.<5I2J>SFI6O835U8^?+#X1^([E%\
MXQV9 Z,N['Y&NEL/@C&H7[?J(E]1&"M>OT5TRQ]:76Q*@CA-/^$GABP?S/*N
M)9._F2[A^1KI+7PQHMF,0Z;;#W,8)_E6O17/*M4G\4F59(CC@BA&(HD0>BC%
M2445D,**** "BBB@ HHHH **** "BBB@#)\3?\BW??\ 7(U\E?#G_DHUE_U\
M?^S5]?ZK9G4-+N+53@RH5!KQKPQ\$+W0_$UOJDEZK+')O*@CUSZ4 >XT444
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M%7ART\4Z!<:9=H&5QE"?X6'0UYO\/_@_>>#_ !(-1EO!)&N, $9- 'L5%%%
M!7G_ ,9O^2;:G_US_J*] KF_'7AR7Q5X5N]*AD$;S+@,?J* /!OV>?\ D<9O
M^N+_ ,A7T[7D_P -/A3=^"=<>_GNEE5HV3:".]>L4 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 V0.8F$;!7(^4D9P:\MNKKX@0>,[7P\/$.G;
MKFVDN5F^P\*%.,8S[UZI7!ZC_P EJT7_ +!,_P#Z&* -;7M3U+1M-L/WT<EP
M[!)GV8#'C) [5!XQ\07NC1Z,;)XP;J^B@EW+G*MUQ57XE6[76DVL"W$ENSRX
M$D>-R].F:Y;Q;X;N]*G\.W$^OW]^AU* >5.%VCGKP* .I\6:EXA_X2'3]*T/
M4+:R\\G<\\'F=LUL>'[/Q':^;_;FKVE\"?D\BW\O'ZUR7CFV6Z\:Z/&VK2Z:
M26Q+$1G[OO78^'8X;6S:W36)-3<=9)"-WZ4 <-HFH>//$5GJ&IVNN:?!;V]W
M/"D#609BL;$=<]Z[CPGK4NN:%#=7,>RXQB51V->9^%(?$9\*ZU+I4\:P#4;O
M*EB"/G.ZNN\+7]GI/PPCU.*9Y!';F61Y<!B03UQ0 RQ\97EQ\0I=-8H=*E41
MVS!1DR+G>,U<^(&L:OI=OI<.C7,-O<7MZEOYDL6\*&SVKS]%U/2= L]2_LTD
M1WCW*3 '.V9@?Y&NK^)4DEU:^&GLW7S'U.(QL3QGF@">/4/%GA[7+&WUS4;7
M4;:\)7,%N(C&0/UJ/7M7\3W?CZ+0-$U.TL8OL;7#//;B3)#8K2B\,ZK?ZS9W
MVL7V4M"2D,9RK$C'-<MXBM!>?%R*,ZO-I8_LUSYT1&3\_3F@#N;"/7]-T2]F
MU?4[:]N(XG>-X8/+ (!(XJ'P5K=[KG@73]6O61KJ> .Y5<#/TJ>W2-?"UY:P
MZB^HNL$@\UB"QRIXXKFOA]J^GV'PUL;:[NXH)[6WV3H[8,9]#0!I>$=9UCQ1
MX.GNA<PPWPNYX4D,65 1R!Q]*QM(F\>W7B.XL)_$.GM':OA\6.-X'ISQ6G\)
MHI(O!;^8A7??7+KD=5,A(/XBIM (_P"$XUG_ 'S_ $H LZIK=_9>-_#^DHZ&
MWO(Y3/\ )R2J@C![<U1UC5/$>I^)VT;0;JWL5AB\R2XGA$H)SC;BF>(?^2J>
M%?\ KG<?^@BEMKZVL/B/>QW<R0M) 60.<9&Z@"_X:O?$$6H7FFZ\T=RT 5H[
MN*/RUDSSC;[5A)JWBOQ)JVJIH^L6.FPV-RUN(;BV$C/CG<#D<<UU>G>*=/U7
M6;W3K(F9[15:21>5Y&0,US+Q>&M<U#4I;:Z?2=1@F,4\JX#EO7F@#J?"]_J&
MH:.LFJ0>3=J[(X[-@XR/KUK:KD?A]JESJ6A,;BX-T(I71;@GEP&(KKJ "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB@".""*VA6*&-4C48"J,"H8=/MH+J6YCC EE.7;UJU10!5ET^VGOH+R2,&>
M$1MZ9ZU6U/0-.U9U>Z@!D48$B\-CTSUQ6G10!1TW1['28V2S@6/=]YL?,WU/
M>JE]X6TF_N6N);?;(W+&,[=Q]3CK6S10!!9V5O86RV]K"D42]%10!4]%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
(% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140043070335640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 28,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PLIANT THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-4272481<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">260 Littlefield Avenue,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco,<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">481-6770<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PLRX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001746473<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>plrx-20220228_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="plrx-20220228.xsd" xlink:type="simple"/>
    <context id="ic10c089cca4b439a8aac7cbb76b6909e_D20220228-20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
        </entity>
        <period>
            <startDate>2022-02-28</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="ic10c089cca4b439a8aac7cbb76b6909e_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjc0ODVhNWM2YmQwYjRlOWI5Y2FmMWExNDRjZmRlN2Q1L3NlYzo3NDg1YTVjNmJkMGI0ZTliOWNhZjFhMTQ0Y2ZkZTdkNV80L2ZyYWc6OTIyNmFiZGVjMmYwNDI0ZmE5NmU2M2FjYzQwMzc3MzYvdGFibGU6NjIwZjFjYmQyOTgwNDU4NjhlOTM1NzE3MThhYzQ0MWIvdGFibGVyYW5nZTo2MjBmMWNiZDI5ODA0NTg2OGU5MzU3MTcxOGFjNDQxYl8wLTEtMS0xLTI5MzAw_fff81ad6-bb31-48ce-bb6b-3e049bd27baf">0001746473</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="ic10c089cca4b439a8aac7cbb76b6909e_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjc0ODVhNWM2YmQwYjRlOWI5Y2FmMWExNDRjZmRlN2Q1L3NlYzo3NDg1YTVjNmJkMGI0ZTliOWNhZjFhMTQ0Y2ZkZTdkNV80L2ZyYWc6OTIyNmFiZGVjMmYwNDI0ZmE5NmU2M2FjYzQwMzc3MzYvdGFibGU6NjIwZjFjYmQyOTgwNDU4NjhlOTM1NzE3MThhYzQ0MWIvdGFibGVyYW5nZTo2MjBmMWNiZDI5ODA0NTg2OGU5MzU3MTcxOGFjNDQxYl8xLTEtMS0xLTI5MzAw_68fa1791-48a1-4f6c-bb03-20ad304a5225">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="ic10c089cca4b439a8aac7cbb76b6909e_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjc0ODVhNWM2YmQwYjRlOWI5Y2FmMWExNDRjZmRlN2Q1L3NlYzo3NDg1YTVjNmJkMGI0ZTliOWNhZjFhMTQ0Y2ZkZTdkNV8xL2ZyYWc6ZjJhN2RjYjI2Y2QzNDVkZDllYjFhYTNjZDJjNTRjOGMvdGV4dHJlZ2lvbjpmMmE3ZGNiMjZjZDM0NWRkOWViMWFhM2NkMmM1NGM4Y18xNDQw_582fb18d-4d69-4b4a-8593-6095210b72ac">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="ic10c089cca4b439a8aac7cbb76b6909e_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjc0ODVhNWM2YmQwYjRlOWI5Y2FmMWExNDRjZmRlN2Q1L3NlYzo3NDg1YTVjNmJkMGI0ZTliOWNhZjFhMTQ0Y2ZkZTdkNV8xL2ZyYWc6ZjJhN2RjYjI2Y2QzNDVkZDllYjFhYTNjZDJjNTRjOGMvdGV4dHJlZ2lvbjpmMmE3ZGNiMjZjZDM0NWRkOWViMWFhM2NkMmM1NGM4Y18xMDk5NTExNjI5MjQz_986ebfe3-f7a3-46c2-a9ea-feaacd89f2fd">2022-02-28</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="ic10c089cca4b439a8aac7cbb76b6909e_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjc0ODVhNWM2YmQwYjRlOWI5Y2FmMWExNDRjZmRlN2Q1L3NlYzo3NDg1YTVjNmJkMGI0ZTliOWNhZjFhMTQ0Y2ZkZTdkNV8xL2ZyYWc6ZjJhN2RjYjI2Y2QzNDVkZDllYjFhYTNjZDJjNTRjOGMvdGV4dHJlZ2lvbjpmMmE3ZGNiMjZjZDM0NWRkOWViMWFhM2NkMmM1NGM4Y18xNDQy_47b7dfed-ef7b-48ab-b007-95230ae449d5">PLIANT THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ic10c089cca4b439a8aac7cbb76b6909e_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjc0ODVhNWM2YmQwYjRlOWI5Y2FmMWExNDRjZmRlN2Q1L3NlYzo3NDg1YTVjNmJkMGI0ZTliOWNhZjFhMTQ0Y2ZkZTdkNV8xL2ZyYWc6ZjJhN2RjYjI2Y2QzNDVkZDllYjFhYTNjZDJjNTRjOGMvdGFibGU6ZjgyNmY0MDMyM2U2NGJlNTk1Nzg1OGViZDg0Njc0MTAvdGFibGVyYW5nZTpmODI2ZjQwMzIzZTY0YmU1OTU3ODU4ZWJkODQ2NzQxMF8wLTAtMS0xLTI5MzAw_809c5e06-ad60-418b-88cb-ebc93455fa35">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="ic10c089cca4b439a8aac7cbb76b6909e_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjc0ODVhNWM2YmQwYjRlOWI5Y2FmMWExNDRjZmRlN2Q1L3NlYzo3NDg1YTVjNmJkMGI0ZTliOWNhZjFhMTQ0Y2ZkZTdkNV8xL2ZyYWc6ZjJhN2RjYjI2Y2QzNDVkZDllYjFhYTNjZDJjNTRjOGMvdGFibGU6ZjgyNmY0MDMyM2U2NGJlNTk1Nzg1OGViZDg0Njc0MTAvdGFibGVyYW5nZTpmODI2ZjQwMzIzZTY0YmU1OTU3ODU4ZWJkODQ2NzQxMF8wLTEtMS0xLTI5MzAw_043d8995-b22c-479c-a8d9-0e402e0cd3e3">001-39303</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="ic10c089cca4b439a8aac7cbb76b6909e_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjc0ODVhNWM2YmQwYjRlOWI5Y2FmMWExNDRjZmRlN2Q1L3NlYzo3NDg1YTVjNmJkMGI0ZTliOWNhZjFhMTQ0Y2ZkZTdkNV8xL2ZyYWc6ZjJhN2RjYjI2Y2QzNDVkZDllYjFhYTNjZDJjNTRjOGMvdGFibGU6ZjgyNmY0MDMyM2U2NGJlNTk1Nzg1OGViZDg0Njc0MTAvdGFibGVyYW5nZTpmODI2ZjQwMzIzZTY0YmU1OTU3ODU4ZWJkODQ2NzQxMF8wLTItMS0xLTI5MzAw_066d8818-0d2a-4a52-b6e0-fd13cec54d29">47-4272481</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ic10c089cca4b439a8aac7cbb76b6909e_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjc0ODVhNWM2YmQwYjRlOWI5Y2FmMWExNDRjZmRlN2Q1L3NlYzo3NDg1YTVjNmJkMGI0ZTliOWNhZjFhMTQ0Y2ZkZTdkNV8xL2ZyYWc6ZjJhN2RjYjI2Y2QzNDVkZDllYjFhYTNjZDJjNTRjOGMvdGFibGU6ZjgyNmY0MDMyM2U2NGJlNTk1Nzg1OGViZDg0Njc0MTAvdGFibGVyYW5nZTpmODI2ZjQwMzIzZTY0YmU1OTU3ODU4ZWJkODQ2NzQxMF8zLTAtMS0xLTI5MzAwL3RleHRyZWdpb246MzE4OGVjYzViNjFlNDQ4MzgzYjhhNTM4MDQ4ZjY0MDBfNQ_ac474ece-8e2a-4b16-a8a7-f5fb40804d8d">260 Littlefield Avenue,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ic10c089cca4b439a8aac7cbb76b6909e_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjc0ODVhNWM2YmQwYjRlOWI5Y2FmMWExNDRjZmRlN2Q1L3NlYzo3NDg1YTVjNmJkMGI0ZTliOWNhZjFhMTQ0Y2ZkZTdkNV8xL2ZyYWc6ZjJhN2RjYjI2Y2QzNDVkZDllYjFhYTNjZDJjNTRjOGMvdGFibGU6ZjgyNmY0MDMyM2U2NGJlNTk1Nzg1OGViZDg0Njc0MTAvdGFibGVyYW5nZTpmODI2ZjQwMzIzZTY0YmU1OTU3ODU4ZWJkODQ2NzQxMF8zLTAtMS0xLTI5MzAwL3RleHRyZWdpb246MzE4OGVjYzViNjFlNDQ4MzgzYjhhNTM4MDQ4ZjY0MDBfOA_a5767c87-f13f-4f5f-ba5e-1795c149aeb7">South San Francisco,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ic10c089cca4b439a8aac7cbb76b6909e_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjc0ODVhNWM2YmQwYjRlOWI5Y2FmMWExNDRjZmRlN2Q1L3NlYzo3NDg1YTVjNmJkMGI0ZTliOWNhZjFhMTQ0Y2ZkZTdkNV8xL2ZyYWc6ZjJhN2RjYjI2Y2QzNDVkZDllYjFhYTNjZDJjNTRjOGMvdGFibGU6ZjgyNmY0MDMyM2U2NGJlNTk1Nzg1OGViZDg0Njc0MTAvdGFibGVyYW5nZTpmODI2ZjQwMzIzZTY0YmU1OTU3ODU4ZWJkODQ2NzQxMF8zLTAtMS0xLTI5MzAwL3RleHRyZWdpb246MzE4OGVjYzViNjFlNDQ4MzgzYjhhNTM4MDQ4ZjY0MDBfMTE_a0866f46-a827-413c-a9f8-ff4878f593fc">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ic10c089cca4b439a8aac7cbb76b6909e_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjc0ODVhNWM2YmQwYjRlOWI5Y2FmMWExNDRjZmRlN2Q1L3NlYzo3NDg1YTVjNmJkMGI0ZTliOWNhZjFhMTQ0Y2ZkZTdkNV8xL2ZyYWc6ZjJhN2RjYjI2Y2QzNDVkZDllYjFhYTNjZDJjNTRjOGMvdGFibGU6ZjgyNmY0MDMyM2U2NGJlNTk1Nzg1OGViZDg0Njc0MTAvdGFibGVyYW5nZTpmODI2ZjQwMzIzZTY0YmU1OTU3ODU4ZWJkODQ2NzQxMF8zLTItMS0xLTI5MzAw_e6a4405c-030e-41a6-ae57-5d807069221f">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ic10c089cca4b439a8aac7cbb76b6909e_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjc0ODVhNWM2YmQwYjRlOWI5Y2FmMWExNDRjZmRlN2Q1L3NlYzo3NDg1YTVjNmJkMGI0ZTliOWNhZjFhMTQ0Y2ZkZTdkNV8xL2ZyYWc6ZjJhN2RjYjI2Y2QzNDVkZDllYjFhYTNjZDJjNTRjOGMvdGV4dHJlZ2lvbjpmMmE3ZGNiMjZjZDM0NWRkOWViMWFhM2NkMmM1NGM4Y18xNDQz_ea19efce-e503-4e24-a41a-ba389c54c9e2">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ic10c089cca4b439a8aac7cbb76b6909e_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjc0ODVhNWM2YmQwYjRlOWI5Y2FmMWExNDRjZmRlN2Q1L3NlYzo3NDg1YTVjNmJkMGI0ZTliOWNhZjFhMTQ0Y2ZkZTdkNV8xL2ZyYWc6ZjJhN2RjYjI2Y2QzNDVkZDllYjFhYTNjZDJjNTRjOGMvdGV4dHJlZ2lvbjpmMmE3ZGNiMjZjZDM0NWRkOWViMWFhM2NkMmM1NGM4Y18xNDQ0_2173851a-dc5f-4e85-9c6e-3c075c7d15fa">481-6770</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="ic10c089cca4b439a8aac7cbb76b6909e_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjc0ODVhNWM2YmQwYjRlOWI5Y2FmMWExNDRjZmRlN2Q1L3NlYzo3NDg1YTVjNmJkMGI0ZTliOWNhZjFhMTQ0Y2ZkZTdkNV8xL2ZyYWc6ZjJhN2RjYjI2Y2QzNDVkZDllYjFhYTNjZDJjNTRjOGMvdGFibGU6NTMxNTdmNzdjNDk0NDg4ZjgwZDUxNjQ4NDFlYjRkNjEvdGFibGVyYW5nZTo1MzE1N2Y3N2M0OTQ0ODhmODBkNTE2NDg0MWViNGQ2MV8wLTAtMS0xLTI5MzAw_4fdd0ca0-7ffc-4667-b5a3-6fdc09fe7432">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="ic10c089cca4b439a8aac7cbb76b6909e_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjc0ODVhNWM2YmQwYjRlOWI5Y2FmMWExNDRjZmRlN2Q1L3NlYzo3NDg1YTVjNmJkMGI0ZTliOWNhZjFhMTQ0Y2ZkZTdkNV8xL2ZyYWc6ZjJhN2RjYjI2Y2QzNDVkZDllYjFhYTNjZDJjNTRjOGMvdGFibGU6NTMxNTdmNzdjNDk0NDg4ZjgwZDUxNjQ4NDFlYjRkNjEvdGFibGVyYW5nZTo1MzE1N2Y3N2M0OTQ0ODhmODBkNTE2NDg0MWViNGQ2MV8yLTAtMS0xLTI5MzAw_2107c958-11ff-44c3-b42e-566a21b195c5">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="ic10c089cca4b439a8aac7cbb76b6909e_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjc0ODVhNWM2YmQwYjRlOWI5Y2FmMWExNDRjZmRlN2Q1L3NlYzo3NDg1YTVjNmJkMGI0ZTliOWNhZjFhMTQ0Y2ZkZTdkNV8xL2ZyYWc6ZjJhN2RjYjI2Y2QzNDVkZDllYjFhYTNjZDJjNTRjOGMvdGFibGU6NTMxNTdmNzdjNDk0NDg4ZjgwZDUxNjQ4NDFlYjRkNjEvdGFibGVyYW5nZTo1MzE1N2Y3N2M0OTQ0ODhmODBkNTE2NDg0MWViNGQ2MV80LTAtMS0xLTI5MzAw_9d5c1b21-18fb-4f48-851c-15b712119a8f">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="ic10c089cca4b439a8aac7cbb76b6909e_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjc0ODVhNWM2YmQwYjRlOWI5Y2FmMWExNDRjZmRlN2Q1L3NlYzo3NDg1YTVjNmJkMGI0ZTliOWNhZjFhMTQ0Y2ZkZTdkNV8xL2ZyYWc6ZjJhN2RjYjI2Y2QzNDVkZDllYjFhYTNjZDJjNTRjOGMvdGFibGU6NTMxNTdmNzdjNDk0NDg4ZjgwZDUxNjQ4NDFlYjRkNjEvdGFibGVyYW5nZTo1MzE1N2Y3N2M0OTQ0ODhmODBkNTE2NDg0MWViNGQ2MV82LTAtMS0xLTI5MzAw_66c0ee75-d8e6-47fb-b14d-b6bacc9cedbb">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="ic10c089cca4b439a8aac7cbb76b6909e_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjc0ODVhNWM2YmQwYjRlOWI5Y2FmMWExNDRjZmRlN2Q1L3NlYzo3NDg1YTVjNmJkMGI0ZTliOWNhZjFhMTQ0Y2ZkZTdkNV8xL2ZyYWc6ZjJhN2RjYjI2Y2QzNDVkZDllYjFhYTNjZDJjNTRjOGMvdGFibGU6NTJjMTkyMzllMzk1NDFjY2I0N2NlYWQzYTMyMzc0NzkvdGFibGVyYW5nZTo1MmMxOTIzOWUzOTU0MWNjYjQ3Y2VhZDNhMzIzNzQ3OV8xLTAtMS0xLTI5MzAw_087390d2-e842-4cef-99a5-b73739e49cb8">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ic10c089cca4b439a8aac7cbb76b6909e_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjc0ODVhNWM2YmQwYjRlOWI5Y2FmMWExNDRjZmRlN2Q1L3NlYzo3NDg1YTVjNmJkMGI0ZTliOWNhZjFhMTQ0Y2ZkZTdkNV8xL2ZyYWc6ZjJhN2RjYjI2Y2QzNDVkZDllYjFhYTNjZDJjNTRjOGMvdGFibGU6NTJjMTkyMzllMzk1NDFjY2I0N2NlYWQzYTMyMzc0NzkvdGFibGVyYW5nZTo1MmMxOTIzOWUzOTU0MWNjYjQ3Y2VhZDNhMzIzNzQ3OV8xLTItMS0xLTI5MzAw_271a6966-964a-46a4-a885-16db83d17304">PLRX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ic10c089cca4b439a8aac7cbb76b6909e_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjc0ODVhNWM2YmQwYjRlOWI5Y2FmMWExNDRjZmRlN2Q1L3NlYzo3NDg1YTVjNmJkMGI0ZTliOWNhZjFhMTQ0Y2ZkZTdkNV8xL2ZyYWc6ZjJhN2RjYjI2Y2QzNDVkZDllYjFhYTNjZDJjNTRjOGMvdGFibGU6NTJjMTkyMzllMzk1NDFjY2I0N2NlYWQzYTMyMzc0NzkvdGFibGVyYW5nZTo1MmMxOTIzOWUzOTU0MWNjYjQ3Y2VhZDNhMzIzNzQ3OV8xLTQtMS0xLTI5MzAw_6cfe474e-de62-421d-bfbd-16bffd3c207b">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="ic10c089cca4b439a8aac7cbb76b6909e_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOjc0ODVhNWM2YmQwYjRlOWI5Y2FmMWExNDRjZmRlN2Q1L3NlYzo3NDg1YTVjNmJkMGI0ZTliOWNhZjFhMTQ0Y2ZkZTdkNV8xL2ZyYWc6ZjJhN2RjYjI2Y2QzNDVkZDllYjFhYTNjZDJjNTRjOGMvdGV4dHJlZ2lvbjpmMmE3ZGNiMjZjZDM0NWRkOWViMWFhM2NkMmM1NGM4Y18xNDQ1_850a1f70-dba2-40fc-8e8c-57251af5a0c7">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( /> 7%0'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " #W@%Q4WTQAU^X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M3L,P#(9?!>7>NLW00%&7"X@32$A, G&+'&^+:-HH,6KW]J1EZX3@ 3C&_O/Y
ML^0&@\(^TG/L T5VE*Y&WW9)8=B( W-0  D/Y$TJ<Z++S5T?O>'\C'L(!C_,
MGD!6U1H\L;&&#4S (BQ$H1N+"B,9[N,);W'!A\_8SC"+0"UYZCA!7=8@]#0Q
M',>V@0M@@C%%G[X+9!?B7/T3.W= G))C<DMJ&(9R6,VYO$,-;T^/+_.ZA>L2
MFPXI_TI.\3'01IPGOZ[N[K</0LM*RJ*2A;S=REI5-^IZ_3ZY_O"["/O>NIW[
MQ\9G0=W K[O07U!+ P04    " #W@%Q4F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M /> 7%0,HDB^0 0  $80   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
ME9C1<N(V%(:OMT^A87K1SI#8%@Z0'<*,0\@NL]DL#6RWTTXOA"U $UMR91G"
MV_?(@$VGYIC<Q);M\_/I2.>7E,%6Z==LS;DA;TDLL[O6VICTH^-DX9HG++M6
M*9?P9JETP@PT]<K)4LU95 0EL4-=M^LD3,C6<% \F^KA0.4F%I)/-<GR)&%Z
M=\]CM;UK>:WC@Q>Q6AO[P!D.4K;B,VZ^IU,-+:=4B43"92:4))HO[UJ!]_&>
M^C:@^.)WP;?9R3VQ75DH]6H;D^BNY5HB'O/06 D&EPT?\3BV2L#QST&T5?ZF
M#3R]/ZH_%IV'SBQ8QD<J_B$BL[YK]5LDXDN6Q^9%;3_S0X=NK%ZHXJSX2[;[
M;WV_1<(\,RHY! -!(N3^RMX.B3@-H&<"Z"& %MS['RHH'YAAPX%66Z+MUZ!F
M;XJN%M$ )Z0=E9G1\%9 G!F.U(;K@6- RCYPPD/8_3Z,G@E[Y(MK0OMM0EU*
M_QON $&)04L,6NAU, SR5[#(C(:!^AN1[)22G4+2/R/YH,(<IH\A\UW*ZWJ(
MA_>OOB 0?@GA7P8QY5JHB(QE1&"<:GEPI6/&?_KPH2'G-R7;#:HXED:8'7GA
M*V&S#I#/+*DEPW6F3Y/@>4[FG\<OP73\?3X9S=ID\CRZ1AB[)6/W$L:)#)5.
ME6:VDMMD9B"%1&DR4KDT>@?7J!8<%W\8(X2]DK!W">&CB#EYSI-%?37A&J[K
M775N.VX'X>F7//U+>.;LC4PBF'EB*<(B;0@=KNCWKGS:HW[?0_!N2[S;2_""
M*-(\R]K'&_($WY%OLG84<47:=2':F)@O!8\C$FRXS'D;8?7<RAS==]&.; OF
MW5QM9:UIXG(S6!;79,8D>81Z"T46*I3SQ,2]=W&6!3+5:B-D6)O6!LU1@*%5
MQN[1=Z%-56983/X4Z=FJ;5"\]=V^B[%5*X2'>WPQG %L9LZCX +=&Q2D6B4\
MW-R?5 @YF:Z5Q$RD000*]*K;ZZ%$U=K@X:;^0T-)<0F)29)<'BPDJZ7"A98L
MSCB&5"T%'F[7,Q6+4!@A5^0K3&\M6%S+@ZLT\E3&[^&N/=7\*H3T<*BO_4:#
MRPAV,=^6RS/CA^LUDE5+@(<[]O_()EF6 UDC("[;"%@M A[NV7,!=DW4DGCT
ME\6O9,;#'.;;KI8)5[+S$]:VF5'A:YND3),-BW-.?G:O75A620K]S=9,8]RT
M6@\H;N!SS2([_V:[9*%J9U^#P/3IY0^,I')\BKOS,65D_!:NF5SQLYNW!J'G
M8/80_(8QG>SA+[+Z<<+URF;I$RC >@=#E#)9.[@-@DT3CE9.3W&C/J"-H!@T
M..T$ZN"-?.'U4+B4G58]O^OWL-T:K:R?XJX=0(%&19$^QFQ5RX,+G$V2<W(J
MM"?LK\P.2T9@HP1"[G4/C%OO#ZW[AE%I<5!<* /'SN)V#0=]KNT'\'ZIE#DV
M[-FS_-?!\%]02P,$%     @ ]X!<5)^@&_"Q @  X@P   T   !X;"]S='EL
M97,N>&ULW5=M:]LP$/XK0C]@;F)JXI$8MD!AL(U"\V%?E5AV!'KQ9+ES^NNG
MLVPG:75EW8>QS:')W3VZNT=W)YFN6W>2_.'(N2.]DKK=T*-SS?LD:0]'KEC[
MSC1<>Z0R5C'G55LG;6,Y*UMP4C)9WMQDB6)"TV*M.W6G7$L.IM-N0V]H4JPK
MH\^6E :#7\H4)X],;NB62;&W8EC+E)"G8%Z"X6"DL<1Y*GQ#%V!IGP*\"!JP
M'.,HH8T%8Q(RA._]N/P9,&FM5X64,\$E#89BW3#GN-5W7AD6#\87$!GEW:GQ
M#&O+3HOE+3T[##\^R=[8DMLYS8).IF(M>05TK*B/\.M,DP#HG%%>* 6KC68#
MA\EC%'S8 Y?R 5KXK;J*W5<D].)3"6T@L-5)](1&,80)"L2_C!9B7X2]_:VP
MI!&/QGWL_&[TH'_OC./WEE>B'_2^FO-CT1=X=-8T\O1!BEHK'O;^RPF+-9O\
MR-%8\>2SP:0<O(%;2AZY=>)P:?EA6;/CO9NFJ:]PSLM_D/.?K7/--;=,7I+V
MH_\W5_DMC)/Q]%P<T:L#.EL)7(0;^A7N5WGF0/:=D$[H43N*LN3ZQ3GUX1W;
M^PO\*KY?7_**==+M9G!#S_(77HI.Y?.J>ZC+N.HL?X;[:)'-M[#/)73)>UYN
M1]76^T$D7O!9QP<<GB-WPQ-',)^ Q1' L#P8 \PG>&%Y_J?]K-#]! SCMHHB
M*]1GA?H$KQBR'3Y8GKA/[I_X3O,\3;,,J^AV&V6PQ>J69? 7CX9Q P\L#V1Z
M6ZWQ;N,3\OH<8#U];4*PG>*3B.T4KS4@\;J!1Y['NXWE 0^L"]CL0/YX'IBI
MN$^:0E<Q;M@)QI$\QQ"8Q?B,9AE2G0P^\?Y@IR1-\SR. !9GD*88 J<11S &
MP %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @ ]X!<5)>*NQS     $P(
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M_S!YU!Y:YU;*O8=7LN48<?R>Y0]02P,$%     @ ]X!<5"0>FZ*M    ^ $
M !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<[61/0Z#, R%KQ+E #50
MJ4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>+7_OR4Z?:!1W;J"V\R1&:P;*
M9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI
M?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI
M5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0    ( /> 7%1ED'F2&0$
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M;W!S+V%P<"YX;6Q02P$"% ,4    " #W@%Q4WTQAU^X    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " #W@%Q4
MF5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( /> 7%0,HDB^0 0  $80   8              "
M@0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " #W@%Q4
MGZ ;\+$"  #B#   #0              @ &##   >&PO<W1Y;&5S+GAM;%!+
M 0(4 Q0    ( /> 7%27BKL<P    !,"   +              "  5\/  !?
M<F5L<R\N<F5L<U!+ 0(4 Q0    ( /> 7%2JQ"(6,P$  "("   /
M      "  4@0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #W@%Q4)!Z;
MHJT   #X 0  &@              @ &H$0  >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    " #W@%Q499!YDAD!  #/ P  $P
M    @ &-$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  #7
%$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>118</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="plrx-20220228.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="plrx-20220228.htm">plrx-20220228.htm</File>
    <File>a4q2021exhibit991.htm</File>
    <File>plrx-20220228.xsd</File>
    <File>plrx-20220228_lab.xml</File>
    <File>plrx-20220228_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "plrx-20220228.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "plrx-20220228.htm"
     ]
    },
    "labelLink": {
     "local": [
      "plrx-20220228_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "plrx-20220228_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "plrx-20220228.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 118,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "plrx",
   "nsuri": "http://www.pliantrx.com/20220228",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20220228.htm",
      "contextRef": "ic10c089cca4b439a8aac7cbb76b6909e_D20220228-20220228",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.pliantrx.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20220228.htm",
      "contextRef": "ic10c089cca4b439a8aac7cbb76b6909e_D20220228-20220228",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001746473-22-000009-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001746473-22-000009-xbrl.zip
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M >STYYU&I@GK^#(0&7*6C1A]^-&7'1FS=KMJ34-\']58#>%;L.P$["ZP080
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M75^"M:8ZBX15R-AJ-$;Y&(^^H 4\,\BQ'*2EXZGQEVF P(+?X60L1G,^1!N
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M^&&U#=-:F.N7_'C^S*MMM%LE0XK#$,<R&DY]:PS9]SSY @=_1:2/UM&G=LF
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M:3IV5")CS:.N8'I,5V2)6RNFKBB?GW>3SRL=N5U1BG-1 QYF90T-9@X!-8:
M:8JDYFBY</B'G_G9$G54WF\@21:*D'&)%91$4\;RUN4,+Q_L/(%W76&E?I[+
MNL&6![#E. 3=#8:N?V'!@LO5D0VP/!E8QG> 11(%W355 XNB!]: XLK8422&
M54TCDNB(INJJOP6PW,H9ZN6"=A=51(5@49H!EKFCA#>PHH#FD.;<(,L:(\N/
MB'&-A5^XDA[3YDIZ5/<\[A;8(,P3$4:X@S F55W1D40L&IZ#%4\QL*&*+A95
M1Q<E481Q\WX+A %YP^Z,P#VJPX@*Q=*6\VDUO,GR;A#G_2!.+8Z'+-K@SG/@
MCG0'=S3-%1C354P-IF%%!_!Q^"QQ-(>XKNDRZC@;W%F*.S+#RI:[&N[D>9\8
M27H[?]Z,29@YV%C$Z%Q?W%PFD6)P[G #_E?RKW$JWI.#3=:*BOZT<Z$/IZGR
M:C>&_90W4"I*YE,)>FUBTY[5/M#1V-5BS$U^T6IV(XG;06Y XOBCA=%??,/Y
M^@6HFA'AG*Q['.UXW'/"8"O^H.>+/N:N%#N_\B(%##95.& !ON[X\,OM*OTS
M>ZSR-9<OR0#O@P3%8>#31^^97-X[;Z?#O:2#-5.$QJ+DI)C]KFV-[UVK>3FV
M)D%@32Y%L"VZ+:DFV!+0<78T:34M2',%>W)YU];H6:-ZLS:IGYU,ZLT3L"UL
M:/M(;DFGG7;%[O"-A/;D2*YS&A=M#<'095.@$F:&(F'%91XV3:)B1Y<A@2FF
MZQB%76[[@3@?)Z%[N8T&)$)7)!@R]+^IUB:B ;^!M_.Q+A7XQ6UUSSI]WY3E
M%YS!^:*<+7J;Z;O"]%W8[ROI(M%,3<.FIA"L:$3!Q#!4+&K4,60JZK*@\"NF
M&G]O9N9F9CYA;9VZ3[([W!8O[>&ZSKN_K^?U)N_1@I_/]1@_08@ITV#ME42*
M'<^A,'D=SZ.R*PFZ X9+AR&;Q)3\DZV_R"+1)4O0X6'Y\2W\Z^W)JO4I]^4Q
MY(R1F^Y2 [(N06MFZ?T0"UO(_!@!B0Q8O>"QSHLHO$XZW"4XX-O*2(PH\Z")
M](:Y;">%H"ZY0_7VZE09;7'0T#_S[=>"^#G=5#$M ZV!Y _X%75\/V/F7I0<
M+*UX+>MBW=SC>%M\IO;[;[Y<BS&J+N_O'&U?^ES0M/6#M/%RUO;'"C;\TJ9H
M\=Q0!2)ZNH"I0P!$!,_%!C-<K.J2*A)/)8*K/QXL6$O1JWD/3/AMF.9+T<._
ML_>T ]C  N;RY\+Z8>HA'\8LS072FN]PY0]>^:G7/'N2@\M8VE8PYHVGSXQQ
MG.D#;Y 2L2L_AG* ./P(+ D0<5U^OQW/S-^%HB2B<;:WE=[GGI>WR(U[?A9#
MBMGLNAFTA4%Z1\[YGW]X8R'B:SP0\5WM+8Z[0=Y[%\79!U$&828.I8@%A)\3
MN_-$RBT9:?O";1'B@$HY3.X6>>Q5E9]^VD4H3 MUHENU_8)A)V+D$A,/5I@2
M":[)."[L//<#,/<'C][BO$0M83TD%05I.GD6_S98/ R2]!A@'>9X'D.$F8KV
M;R9Q.010F;V/ZBUP;R6-(*TKG:N @V":E!23&S-O!-7U/EI^S_<V^A'X'/=
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M-:O9OTY(Q_!/)^D%N_\/4$L#!!0    ( /> 7%323-4*;@(  'H'   1
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M'A@=QL"$.Y@OEW"TM7^S>"+>&1XXVKO[HGOI'LP_VOL_4$L! A0#%     @
M]X!<5%*VJ/"<'@  ;&(! !4              ( !     &$T<3(P,C%E>&AI
M8FET.3DQ+FAT;5!+ 0(4 Q0    ( /> 7%2K";=B[!0  +V8   1
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64$L%!@     %  4 1P$  -E'      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
